New partnership aims to fast-track mRNA therapies from lab to clinic
Quotient Sciences and CPI have signed a memorandum of understanding to form a joint venture focused on accelerating RNA-based drug development. The collaboration will integrate both companies’ technologies to streamline the creation of mRNA therapeutics.
The venture will combine Quotient’s Translational Pharmaceutics platform with CPI’s expertise in RNA synthesis and lipid nanoparticle (LNP) encapsulation. Together, they aim to deliver a first-of-its-kind solution for mRNA drug product development.
Thierry Van Nieuwenhove, CEO at Quotient Sciences, said: “This is a pivotal moment for RNA drug development. The combined innovation and deep technical expertise of Quotient and CPI will enable developers to benefit from a vastly accelerated supply chain, with clinical batches going from plasmid to clinical dose in as little as two months.”
The joint venture will offer integrated mRNA synthesis, LNP formulation, clinical manufacturing, and early-phase testing. This approach allows developers to adjust dose and formulation based on real-time clinical data, potentially improving outcomes in delivery-sensitive modalities.
Frank Millar, CEO at CPI, said: “We’re proud to be partnering with Quotient Sciences on this initiative which represents a bold step forward for the RNA ecosystem. Our shared vision is to enable scalable and sustainable development pathways for mRNA therapies that meet global health challenges head-on.”
Translational Pharmaceutics has supported over 500 programmes globally for small molecule and peptide candidates. This new venture marks its expansion into mRNA therapeutics.
Further details including the venture’s name, branding, and operational roadmap will be announced as the collaboration progresses.